STOCK TITAN

VSee Health, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

VSee Health (Nasdaq: VSEE) has received a notice from Nasdaq on September 6, 2024, stating that the company is not in compliance with listing rule 5250(c)(1) due to the delayed filing of its Q2 2024 Form 10-Q. This non-compliance does not immediately affect the listing or trading of VSee's stock on The Nasdaq Capital Market. The company has until November 5, 2024 to submit a compliance plan to Nasdaq. If accepted, VSee may be granted up to 180 calendar days (until February 18, 2025) to regain compliance. VSee intends to take necessary steps to file the Form 10-Q and regain compliance as soon as possible.

VSee Health (Nasdaq: VSEE) ha ricevuto una comunicazione da Nasdaq il 6 settembre 2024, che informa che la società non è conforme alla norma di quotazione 5250(c)(1) a causa del ritardo nella presentazione del suo modulo 10-Q del secondo trimestre 2024. Questa non conformità non influisce immediatamente sulla quotazione o sul trading delle azioni di VSee sul Nasdaq Capital Market. La società ha tempo fino al 5 novembre 2024 per presentare un piano di conformità a Nasdaq. Se accettato, a VSee potrebbe essere concessa fino a 180 giorni di calendario (fino al 18 febbraio 2025) per recuperare la conformità. VSee intende intraprendere le misure necessarie per presentare il modulo 10-Q e ripristinare la conformità il prima possibile.

VSee Health (Nasdaq: VSEE) ha recibido un aviso de Nasdaq el 6 de septiembre de 2024, indicando que la compañía no cumple con la regla de cotización 5250(c)(1) debido a la presentación retrasada de su formulario 10-Q del segundo trimestre de 2024. Esta falta de cumplimiento no afectará inmediatamente la cotización o el comercio de las acciones de VSee en el Nasdaq Capital Market. La compañía tiene hasta el 5 de noviembre de 2024 para presentar un plan de cumplimiento a Nasdaq. Si es aceptado, se podría conceder a VSee hasta 180 días naturales (hasta el 18 de febrero de 2025) para recuperar la conformidad. VSee tiene la intención de tomar las medidas necesarias para presentar el formulario 10-Q y recuperar la conformidad lo antes posible.

VSee Health (Nasdaq: VSEE)는 2024년 9월 6일 Nasdaq으로부터 공지를 받았습니다. 이 공지에서는 회사가 2024년 2분기 10-Q 양식의 제출 지연으로 인해 상장 규정 5250(c)(1)에 불합격했다고 합니다. 이 불합격은 VSee의 주식이 Nasdaq 자본 시장에서 상장되거나 거래되는 데 즉각적인 영향을 미치지 않습니다. 회사는 Nasdaq에 대응 계획을 제출할 수 있는 기한을 2024년 11월 5일까지 갖습니다. 계획이 수락되면 VSee는 180일까지 (2025년 2월 18일까지) 준수를 회복할 수 있는 시간을 부여받을 수 있습니다. VSee는 10-Q 양식을 제출하고 가능한 한 빨리 준수를 회복하기 위해 필요한 조치를 취할 계획입니다.

VSee Health (Nasdaq: VSEE) a reçu un avis de Nasdaq le 6 septembre 2024, indiquant que l'entreprise n'est pas en conformité avec la règle de cotation 5250(c)(1) en raison du retard dans le dépôt de son formulaire 10-Q du deuxième trimestre 2024. Cette non-conformité n'affecte pas immédiatement la cotation ou le trading des actions de VSee sur le Nasdaq Capital Market. L'entreprise a jusqu'au 5 novembre 2024 pour soumettre un plan de conformité à Nasdaq. Si accepté, VSee pourrait se voir accorder jusqu'à 180 jours calendaires (jusqu'au 18 février 2025) pour rétablir la conformité. VSee a l'intention de prendre les mesures nécessaires pour déposer le formulaire 10-Q et retrouver la conformité dès que possible.

VSee Health (Nasdaq: VSEE) erhielt am 6. September 2024 eine Mitteilung von Nasdaq, in der festgestellt wird, dass das Unternehmen die Zulassungsregel 5250(c)(1) aufgrund der verspäteten Einreichung seines Q2 2024 Formulars 10-Q nicht einhält. Diese Nichteinhaltung hat keine unmittelbaren Auswirkungen auf die Listung oder den Handel der VSee-Aktien am Nasdaq Capital Market. Das Unternehmen hat bis zum 5. November 2024 Zeit, einen Compliance-Plan bei Nasdaq einzureichen. Wenn dieser akzeptiert wird, kann VSee bis zu 180 Kalendertage (bis zum 18. Februar 2025) Zeit erhalten, um die Compliance wiederherzustellen. VSee beabsichtigt, die erforderlichen Schritte zu unternehmen, um das Formular 10-Q einzureichen und so schnell wie möglich wieder compliant zu werden.

Positive
  • None.
Negative
  • Delayed filing of Q2 2024 Form 10-Q
  • Non-compliance with Nasdaq listing rule 5250(c)(1)
  • Risk of potential delisting if compliance is not regained

This delay in filing the Form 10-Q raises significant concerns about VSee Health's financial reporting processes and internal controls. Such delays often indicate underlying issues that could impact investor confidence. The non-compliance with Nasdaq's listing rules puts the company at risk of potential delisting if not addressed promptly. While the immediate trading impact is minimal, this situation could lead to increased volatility and reduced investor interest in the short term. The company's ability to meet the November 5 deadline for submitting a compliance plan will be crucial. Investors should closely monitor the company's progress and any subsequent filings for a clearer picture of its financial health and operational stability.

VSee Health's failure to file its 10-Q on time is a serious regulatory issue. This non-compliance with SEC requirements could potentially expose the company to legal risks and penalties. The 60-day window to submit a compliance plan to Nasdaq is standard procedure, but it's important to note that acceptance of the plan is not guaranteed. If accepted, the extended deadline of up to 180 days provides some breathing room, but also prolongs uncertainty for stakeholders. Investors should be aware that continued non-compliance could lead to more severe consequences, including potential delisting from Nasdaq. This situation underscores the importance of robust financial reporting systems and the potential repercussions of failing to meet regulatory obligations.

BOCA RATON, Fla.--(BUSINESS WIRE)-- VSee Health, Inc. (the “Company”) (Nasdaq: VSEE), announced today that on September 6, 2024, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq’s listing rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission (the “SEC”).

The Nasdaq notice has no immediate effect on the listing or trading of the Company’s common stock or its public warrants on The Nasdaq Capital Market. The Company has until November 5, 2024 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q’s original due date, or until February 18, 2025, to regain compliance. The Company intends to take the necessary steps to regain compliance with Nasdaq’s listing rules and file the Form 10-Q as soon as practicable.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as “believes,” “expects,” “intends,” “plans,” “estimates,” “assumes,” “may,” “should,” “will,” “seeks,” or other similar expressions. Such statements may include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s listing rules within the required timeframe. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly, including those risks set forth in the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and other documents filed with the SEC. Copies of such filings are available on the SEC’s website at www.sec.gov. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

LHA Investor Relations

Tirth T. Patel

212-201-6614

tpatel@lhai.com

Source: VSee Health, Inc.

FAQ

Why did VSee Health (VSEE) receive a notice from Nasdaq on September 6, 2024?

VSee Health received a notice from Nasdaq because it had not filed its Quarterly Report on Form 10-Q for Q2 2024, violating Nasdaq's listing rule 5250(c)(1) which requires timely filing of periodic financial reports.

What is the deadline for VSee Health (VSEE) to submit a compliance plan to Nasdaq?

VSee Health has until November 5, 2024, to submit a plan to Nasdaq to regain compliance with the listing rules.

How long does VSee Health (VSEE) have to regain compliance with Nasdaq listing rules?

If Nasdaq accepts VSee Health's compliance plan, the company may be granted up to 180 calendar days from the original Form 10-Q due date, or until February 18, 2025, to regain compliance.

Will the Nasdaq notice immediately affect VSee Health's (VSEE) stock listing or trading?

No, the Nasdaq notice has no immediate effect on the listing or trading of VSee Health's common stock or public warrants on The Nasdaq Capital Market.

VSee Health, Inc.

NASDAQ:VSEE

VSEE Rankings

VSEE Latest News

VSEE Stock Data

23.56M
14.82M
68.45%
3.41%
0.24%
Health Information Services
Services-health Services
Link
United States of America
BOCA RATON